series

Drug Money

FDA user fee negotiations illustrate a broader phenomenon: the pharmaceutical industry’s influence over many institutions that are supposed to serve as checks on its interests.

Latest

FDA Set Low Bar for Approval of Blood Thinners

analysis | December 12, 2016 | David S. Hilzenrath

Read

Latest

FDA Depends on Industry Funding; Money Comes with “Strings Attached”

investigation | December 1, 2016 | David S. Hilzenrath

Read

In FDA Meetings, "Voice" of the Patient Often Funded by Drug Companies

investigation | December 1, 2016 | David S. Hilzenrath
Drug Problems: Did Bad Blood Tests Turn a Clinical Trial into a Mistrial?

analysis | March 15, 2016 | David S. Hilzenrath
Drug Problems: European Regulator Investigating Trial Led by FDA Nominee

analysis | November 30, 2015 | David S. Hilzenrath
Drug Problems: Duke Reassessing Data From Trial Led By FDA Nominee

analysis | November 20, 2015 | David S. Hilzenrath
Drug Problems: Nominee to Head FDA Led Clinical Trial FDA Faulted

analysis | November 12, 2015 | David S. Hilzenrath
Drug Problems: Dangerous Decision-Making at the FDA

investigation | October 15, 2015 | David S. Hilzenrath